Results 181 to 190 of about 30,028 (235)
Some of the next articles are maybe not open access.
Journal of Clinical Lipidology, 2019
BACKGROUND Current data from individual studies present conflicting evidence about the relationship between risk factors and cardiovascular disease (CVD) in heterozygous familial hypercholesterolemia (FH).
Leo E Akioyamen, , Anna Chu
exaly +2 more sources
BACKGROUND Current data from individual studies present conflicting evidence about the relationship between risk factors and cardiovascular disease (CVD) in heterozygous familial hypercholesterolemia (FH).
Leo E Akioyamen, , Anna Chu
exaly +2 more sources
Severe xanthomatosis in heterozygous familial hypercholesterolemia
Journal of Clinical Lipidology, 2018Familial hypercholesterolemia is a genetic lipoprotein disorder characterized by elevated plasma low-density lipoprotein cholesterol level, (tendinous xanthomas, xanthelasmas, and premature arcus corneus) and early onset atherosclerotic cardiovascular disease. Familial hypercholesterolemia is caused by mutations in the low-density lipoprotein receptor,
Sumayah, Aljenedil +3 more
openaire +3 more sources
Peripheral arterial disease in heterozygous familial hypercholesterolemia
Atherosclerosis, 2015Familial hypercholesterolemia is characterized by elevated plasma cholesterol and early coronary arterial disease onset. However, few studies investigated the association of heterozygous familial hypercholesterolemia with peripheral arterial disease.In a cross sectional study 202 heterozygous familial hypercholesterolemia patients (91% confirmed by ...
Carolina Pereira +2 more
exaly +3 more sources
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
Atherosclerosis, 2019Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and increased cardiovascular disease risk. Despite multiple LDL-C-lowering therapies, many HeFH patients do not reach LDL-C targets. Mipomersen, an antisense oligonucleotide against apolipoprotein B (apoB),
Laurens F. Reeskamp +6 more
openaire +3 more sources
Novel treatment options for the management of heterozygous familial hypercholesterolemia
Expert Review of Clinical Pharmacology, 2017Even though statins represent the mainstay of treatment of heterozygous familial hypercholesterolemia (FH), their low-density lipoprotein cholesterol (LDL-C) lowering efficacy is finite and most patients with FH will not achieve LDL-C targets with statin monotherapy.
Georgios Polychronopoulos +1 more
exaly +3 more sources
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
Atherosclerosis, 2004 Familial hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism characterized by very high plasma concentrations of low density lipoprotein cholesterol (LDLc), tendon xanthomas and increased risk of premature coronary heart disease (CHD). FH is a public health problem throughout the world.
Civeira, Fernando
openaire +3 more sources
Unveiling Compound Heterozygous Familial Hypercholesterolemia
Journal of Clinical Lipidology, 2022Daniel Soffer, Sohil Golwala
openaire +2 more sources
Journal of Clinical Lipidology, 2021
BACKGROUND PCSK9 inhibitors are a treatment option for patients with familial hypercholesterolemia not on low-density lipoprotein cholesterol goals despite the use of maximally tolerated high intensity-statins dose.
R. Alonso +19 more
semanticscholar +1 more source
BACKGROUND PCSK9 inhibitors are a treatment option for patients with familial hypercholesterolemia not on low-density lipoprotein cholesterol goals despite the use of maximally tolerated high intensity-statins dose.
R. Alonso +19 more
semanticscholar +1 more source
Heterozygous Familial Hypercholesterolemia
Circulation, 2016Familial hypercholesterolemia (FH) is a genetic condition that causes high low-density lipoprotein (LDL) cholesterol (sometimes referred to as bad cholesterol) from birth. FH means high cholesterol that runs in a family. FH is caused by specific DNA changes that are passed on from parents to their children. It is not caused by lifestyle factors such as
Angela, Onorato, Amy C, Sturm
openaire +2 more sources
The Detection of Heterozygous Familial Hypercholesterolemia in Ireland
Advances in Therapy, 2012Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant condition with a population prevalence of 1 in 500, and is associated with significant cardiovascular morbidity and mortality. It may be caused by mutations in the low-density lipoprotein (LDL) receptor, apolipoprotein B100 (Apo B100), or proprotein convertase subtilisin/kexin ...
O'Kane, Maurice J +6 more
openaire +3 more sources